基于“调和肝脾”论述肝纤维化与肠道菌群的关系

Association between liver fibrosis and gut microbiota based on “harmonizing liver and spleen”

肝纤维化是全球肝病发病和死亡的主要原因,已成为国内外学者研究慢性肝病的焦点问题之一。越来越多的证据表明肠道菌群失调在肝纤维化发生、发展中的核心作用,改善肠道菌群失衡成为抗纤维化治疗的新靶点。目前中医药在改善肠道菌群方面的相关研究备受瞩目。研究表明,“调和肝脾”在减轻纤维化程度、延缓肝纤维化进展中发挥重要作用。因此,本文基于“调和肝脾”理论分析利用现代分子生物学技术研究肠肝轴与肠道菌群的成果,为临床从“调和肝脾”论治肝纤维化提供有利的理论基础,为中医药抗肝纤维化提供新方向和新思路。

Liver fibrosis is the leading cause of the morbidity and mortality of liver diseases worldwide and has become one of the key issues in the research on chronic liver diseases among domestic and foreign scholars.An increasing amount of evidence has shown that gut microbiota dysbiosis plays a crucial role in the development and progression of liver fibrosis,and improvement of gut microbiota dysbiosis has become a new target for anti-fibrotic treatment.At present,traditional Chinese medicine has attracted much attention in improving gut microbiota.Studies have shown that “harmonizing liver and spleen” plays an important role in reducing fibrosis degree and delaying the progression of liver fibrosis.Therefore,based on the theory of “harmonizing liver and spleen”,the achievements in liver-gut axis and gut microbiota by modern molecular biological techniques can provide a theoretical basis for the treatment of liver fibrosis from “harmonizing liver and spleen” in clinical practice,as well as new directions and ideas for anti-fibrotic treatment with traditional Chinese medicine.